复方苦参注射液联合化疗治疗晚期胃癌的临床观察

目的：评价复方苦参注射液联合化疗治疗晚期胃癌的疗效、KPS评分及对T细胞亚群的作用。方法：将90例晚期胃癌患者随机分为治疗组（复方苦参注射液＋化疗组）和对照组（化疗组）。对照组应用多西他赛、奥沙利铂、氟尿嘧啶联合化疗，治疗组同时加用复方苦参注射液20ml／d静滴，连用2周，3周为一周期。结果：治疗组临床获益率（CR＋PR＋SD）77．08％，明显优于对照组为（61．90％）（P=0．029）；治疗组、对照组Kamofsky评分提高率分别为60．4％和42．9％，两组对比有显著性差异（P=0．024）；治疗组CD4及CD8阳性细胞的百分率分别是39．2±1．9和26．5±1．4，对照组分别是30．8±1．7和23．0±1．8，治疗组高于对照组（P=0．000）。结论：复方苦参注射液联合化疗治疗晚期胃癌有改善生活质量，提高免疫功能，增强化疗效果的作用。

Clinical observation on treating advanced gastric cancer with Fufangkushen injection plus chemotherapy

Objective： To evaluate the effective of treating advanced gastric cancer with Fufangkushen injection plus chemotherapy, KPS （scores of quality of life） and T cell subsets. Methods： 90 cases of advanced gastric cancer are randomly divide in treatment group （Fufangkushen injection＋chemotherapy） and control group （chemotherapy）. control group were treated with joint chemotherapy of doceta -xel, oxaliplatin, fluorouracil, treatment group bases on joint chemotherapy add to Fufangkushen injection （20ml/d,d1-14）, used 2 weeks, 3 weeks are one treatment. Results： Treatment group clinical benefit rate （CR＋PR＋SD） is 77.08%, is better than control group （61.90%） （ P=0.029）; Karnofsky score increased rate of treatment group and control group are 60.4%, 42.9%, two groups have significant defference （P=0.024）; treatment group positive cells rate of CD4 and CD8 are 39.2±1.9 and 26.5±1.4, control group are 30.8±1.7and 23.0il.8, treatment group is higher than control group （P=0.000）. Conclusion： Treating advanced gastric cancer with Fufangkushen injection plus chemotherapy can improve quality of life, immune function, enhance the effect of chemotherapy.